摘要
目的通过前瞻性随机对比研究,观察非诺贝特联合阿托伐他汀对高TG的2型糖尿病患者药物洗脱支架置入术后的临床疗效。方法入选符合本研究标准的522例药物洗脱支架置入术后高TG的2型糖尿病患者,随机分为两组,联合治疗组249例,非诺贝特200mg晨日一次口服,阿托伐他汀20mg晚日一次口服;阿托伐他汀组273例,20mg晚日一次口服。疗程12个月。比较两组主要不良心血管事件发生情况、降脂疗效及安全性。结果非诺贝特联合阿托伐他汀组主要不良心血管事件发生率及血清TG明显低于阿托伐他汀组(P<0.05),而HDL-C明显高于阿托伐他汀组(P<0.05)。不良反应发生率相似。结论非诺贝特联合阿托伐他汀明显改善高TG的2型糖尿病患者药物洗脱支架置入术后的预后,两药联合安全有效。
Objective Through prospective randomized comparative study,to observe the clinical effects of fenofibrate combined with atorvastatin on the high TG type 2 diabetics after DES-PCI.Methods 522 DES-PCI postoperative patients of the high TG type 2 diabetic were selected on the criteria and divided randomly into Fenofibrate combined with atorvastatin group and Atorvastatin group.The 249 patients in the combined group ware treated with Fenofibrate 200mg/d in the morning and Atorvastatin 20mg/d at night.The 273 patients in Atorvastatin group were treated with Atorvastatin 20mg/d at night.The occurrence of major adverse cardiovascular events,lipid-lowering effect and safety in the two groups were comparing during the entire course of treatment totaling 12 months.Results In the hospitalization,the incidence of adverse cardiac and serum TG in the combined group was significantly lower than it in Atorvastatin group（P0.05）.But the incidence of HDL-C in the combined group was significantly higher than it in the atorvastatin group（P0.05）.The incidence of adverse reactions in two groups is similar.Conclusion Fenofibrate combined with atorvastatin can significantly improve the prognosis of the high TG type 2 diabetics after DES-PCI.Fenofibrate combined with atorvastatin is safe and effective.
出处
《中国医药指南》
2012年第35期41-43,共3页
Guide of China Medicine
